Cramer’s One-on-One with Immunogen CEO
Despite today's tough market environment, there are still some stocks speculating on, said Jim Cramer on CNBC’s “Mad Money.”
“If anything, the pervasive sense of fear and pessimism is creating opportunities,” Cramer explained. “You just need to know where to look.”
Take ImmunoGen, for example. Cramer has long liked this speculative biotechnology company, which develops next generation cancer treatments. Its technology allows cancer drugs to target and kill cancer cells while leaving the rest of the body mostly unharmed. At the American Society of Clinical Oncology’s annual meeting on Monday, the company released bullish data on two drugs it’s working on, including T-DM1, a breast cancer drug that it’s developing with , as well as a non-Hodgkin’s lymphoma drug that Sanofi’s developing by using ImmunoGen’s technology.